We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+48.43%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.61B
AUM Growth
+$2.03B
Cap. Flow
+$675M
Cap. Flow %
12.03%
Top 10 Hldgs %
60.15%
Holding
73
New
17
Increased
18
Reduced
15
Closed
18

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$124M
2
VERA icon
Vera Therapeutics
VERA
+$100M
3
GRAL
GRAIL Inc
GRAL
+$88.4M
4
ALKS icon
Alkermes
ALKS
+$59.9M
5
SLNO
Soleno Therapeutics
SLNO
+$54.8M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$190M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$159M
3
TERN
Terns Pharmaceuticals
TERN
+$155M
4
ETNB
89bio
ETNB
+$138M
5
GH icon
Guardant Health
GH
+$121M

Sector Composition

Rank Sector Weight
1 Healthcare 78.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$1.22B 21.74%
+10,000,000
New +$1.15B
IMVT icon
2
Immunovant
IMVT
$8.09B
$293M 5.22%
11,526,971
+1,798,126
+18% +$40.1M
GH icon
3
Guardant Health
GH
$19.5B
$286M 5.1%
2,800,000
-1,354,086
-33% -$121M
GPCR icon
4
Structure Therapeutics
GPCR
$3.49B
$286M 5.1%
4,111,782
-104,029
-2% -$4.25M
TARS icon
5
Tarsus Pharmaceuticals
TARS
$2.56B
$246M 4.39%
3,004,034
+4,034
+0.1% +$301K
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$242M 4.31%
15,726,349
– –
CYTK icon
7
Cytokinetics
CYTK
$11B
$212M 3.78%
3,336,998
-963,002
-22% -$59.9M
AXSM icon
8
Axsome Therapeutics
AXSM
$12.4B
$210M 3.74%
1,150,000
+250,000
+28% +$34.9M
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
$195M 3.47%
7,750,000
-250,382
-3% -$5.87M
PCVX icon
10
Vaxcyte
PCVX
$7.89B
$185M 3.29%
4,000,000
+1,000,000
+33% +$44.7M
MAZE
11
Maze Therapeutics
MAZE
$1.53B
$176M 3.14%
4,246,440
+297,530
+8% +$10.2M
VERA icon
12
Vera Therapeutics
VERA
$2.54B
$143M 2.55%
+2,821,135
New +$100M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.5B
$137M 2.44%
2,300,000
+2,275,144
+9,153% +$124M
IONS icon
14
Ionis Pharmaceuticals
IONS
$9.35B
$134M 2.4%
1,700,000
-2,108,144
-55% -$159M
NRIX icon
15
Nurix Therapeutics
NRIX
$2.43B
$133M 2.38%
7,036,455
+979,431
+16% +$14.1M
MBX
16
MBX Biosciences
MBX
$2.95B
$102M 1.83%
3,249,790
+99,790
+3% +$2.42M
OCUL icon
17
Ocular Therapeutix
OCUL
$1.86B
$98M 1.75%
8,070,414
-3,861,723
-32% -$46.9M
GRAL
18
GRAIL Inc
GRAL
$2.91B
$87.5M 1.56%
+1,022,797
New +$88.4M
VRDN icon
19
Viridian Therapeutics
VRDN
$2.13B
$78.6M 1.4%
2,524,833
-2,855,616
-53% -$78.3M
LBRX
20
LB Pharmaceuticals
LBRX
$1B
$74.6M 1.33%
3,352,804
– –
IMCR icon
21
Immunocore
IMCR
$1.78B
$69.6M 1.24%
2,003,978
+203,978
+11% +$7.2M
ORKA
22
Oruka Therapeutics
ORKA
$5.56B
$65.5M 1.17%
2,161,510
-493,271
-19% -$13.7M
BBIO icon
23
BridgeBio Pharma
BBIO
$16.5B
$62M 1.1%
810,142
-389,858
-32% -$25.6M
CRMD icon
24
CorMedix
CRMD
$617M
$61.3M 1.09%
5,274,076
+4,774,076
+955% +$52.8M
MLTX icon
25
MoonLake Immunotherapeutics
MLTX
$1.59B
$60.8M 1.08%
+4,610,071
New +$54.4M
1
2 3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
GA
Greenhaven Associates Purchase, New York $6.07B AUM 11.2% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return

Deep Track Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Deep Track Capital held 73 positions worth $5.61B, up 57% from $3.58B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Deep Track Capital deployed $675M of net new capital in Q4 2025, opening 17 new positions and adding to 18 existing holdings. Its largest new stake was Vera Therapeutics: 2,821,135 shares worth $143M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $159M trimmed.

  • Deep Track Capital's largest Q4 2025 buy was Vera Therapeutics: 2,821,135 shares worth $143M.
  • Deep Track Capital added most to BioMarin Pharmaceuticals in Q4 2025, an estimated $124M increase.
  • Deep Track Capital's biggest Q4 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $159M.
  • Deep Track Capital fully exited Akero Therapeutics in Q4 2025, selling an estimated $190M.
  • Deep Track Capital's ten largest holdings make up 60% of its $5.61B portfolio in Q4 2025.
  • Deep Track Capital opened 17 new positions and closed 18 in Q4 2025.
  • Deep Track Capital's portfolio value rose 57% quarter-over-quarter to $5.61B.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.